Remove Compliance Remove Insulin Remove Pharmacy
article thumbnail

Droplet Micron Insulin Needle Offers Innovation in Crowded Diabetes Supply Market

XTalks

Being hailed as the world’s shortest and thinnest needle for insulin injection, Droplet Micron has recently been introduced into the pen needle market by HTL (High Tech Lab)-STREFA, Inc. These are important feature innovations for those that depend on insulin injections. Droplet Micron is now available at local pharmacies.

Insulin 98
article thumbnail

FDA Warns About Compounded Versions of Ozempic and Wegovy

XTalks

GLP-1 stimulates insulin production, thus reducing blood glucose levels, and it interacts with the brain to suppress appetite and create a feeling of fullness. mg and 1 mg doses will be available to wholesalers for distribution to retail pharmacies. Despite this, Novo Nordisk doesn’t anticipate interruptions in supplying 1.7

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Top 10 Medical Device Companies in 2023 by Revenue Statistics and Trends

XTalks

Internationally, Medtronic expanded its MiniMed 780G insulin pump and Guardian 4 sensor. BD completed the acquisition of Parata Systems , an innovative provider of pharmacy automation solutions, on July 18, 2022. It also plans to launch these products in the US.

article thumbnail

CMS Finalizes Guidance on Medicare Part D Manufacturer Discount Program

FDA Law Blog

Manufacturers must also ensure that all electronic FDA listings and all NDC listings with the electronic database vendors used to process pharmacy claims, including information about discontinued drugs, are up to date for all applicable drug and selected drug NDCs. covered insulin product or vaccine). 1395w-114c(b)(4)(B)(i).

article thumbnail

Pricing, Profits and Progress: Pharma’s Post-COVID Priorities

pharmaphorum

The fundamental misconception among the public, the media and even some lawmakers is that higher drug list prices are the result of drug manufacturers being in a monopolistic position to endlessly raise prices on critical drugs like insulin and then rake in big profits. Is the Middleman at Fault? About the author.